Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Comment by NamesJebon Oct 26, 2020 12:01pm
115 Views
Post# 31781611

RE:RE:RE:RE:RE:RE:Buyout framework

RE:RE:RE:RE:RE:RE:Buyout framework
Yes you can "legally?" purchase Ifenprodil from Japan if you're suffering from dizziness right now. Algernon Pharmaceuticals is now 1st in line to own the rights to Ifenprodil to treat Covid-19, IPF and Chronic cough however. From my understanding this means if proven successful these Japanese and whatever other companies that are currently manufacturing it can't just suddenly add that it treats covid-19, IPF and Chronic cough and start distributing for those treatments. That would be patent infringement. AGN would choose who manufactures the drug and negotiate the terms of what % profit the drug makers would take. Sure you could probably just buy the drug still directly from Japan knowing it's the same drug and hope it arrives before you either die or get better (not possible even with the expedited shipping option). But the vast majority of people would get it from their local hospital or doctor who would follow the legal procurement process. (I'm not a lawyer, but this is my understanding from my own patent research)
<< Previous
Bullboard Posts
Next >>